Naslov
Lung cancer – experience of a small center.

Autori
Kovač Peić, Anamarija ; Kršan, Matea ; Borić Mikez, Zvjezdana ; Vučinić Ljubičić, Ivana ; Holik, Hrvoje ; Coha, Božena

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Libri Oncologici / - , 2017, 59-59

Skup
1st Regional Congress of Medical Oncology 1st Regional Congress of Oncology Pharmacy

Mjesto i datum
Dubrovnik, Hrvatska, 04.05.2017. - 07.05.2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
Lung cancer ; general hospital ; experience

Sažetak
Objective of this study was to determine median overall survival of the patients treated of lung cancer at the Department of hematology and oncology General hospital Dr. Josip Benčević in Slavonski Brod, also we analized characteristics of patients and treatment based on medical records. Retrospectively we analized data of 195 patients treated in period of 40 months from 09/2013 to 12/2016. It was 151 men (77.4%) and 44 women (22.6%), median age at the time of diagnosis was 65 years range form 43 to 81 years. There were 84% patients with non small lung cancer (NSCLC), 42% had squamous lung cancer, 31% adenocarcinoma, 9% adenosquamous or large cell carcinoma, 2% large cell neuroendocrine carcinoma, 16% patient had smal cell lung cancer. Of all NSCLC 5% had EGFR mutation, and only 4% of patient had ALK determined. Concerning staging 1.2% classifi ed as stage I, 3.5% as stage II, 22.5% as stage III and unfortunately majority of them 72.8% patients as stage IV. Most of them were smokers (74%) and routinely drinking alcohol (27%). At the time of dijagnosis 60% of patients met criteria for cahexia diagnosis. After the fi rst examination of medical oncologist 15 patients (7.7%) were send to thoracic surgery, and 7 patients (3.5%) were operated after neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy. Chemotherapy was administered primarily in outpatients environments. We analized numbers od chemotherapy lines during treatment of each patient: 46% of patients received only one line of treatment, 27% received two lines, 18% three lines, four and more lines of chemotherapy was given to 9% of patients. Time to progression in fi rst line of treatment was 6.6 months. With concomitant chemoradiotherapy we treated 10% of patients, palliative radiation 18% of patients and intrapericardial chemotherapy for pericardial tamponade in 4 patients (2%). Neutropenia durig fi rst line of treatment was identifi ed in 10% of patients, due to complications of treatment 50% of patients was admitt ed to our hospital department one or two times, but 22.% patients were never hospitalized. One year survival was 38.6%. Median overal survival was 11.79 months. Due to new studies in lung cancer that are chaging perspectives for some patients recently treated with chemotherapy and prolong survival we hope that for our patients molecular diagnostic methods will be more available in order to select potential candidates for already approved but also for novel treatments in era of individualized oncology treatment.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA